Cleared Traditional

K860537 - THE CELL CARE SYSTEM

K860537 is an FDA 510(k) clearance for THE CELL CARE SYSTEM, manufactured by The Clell Corp.. The device is a Class 1 General Hospital device with product code KMI cleared through the Traditional 510(k) pathway after a 65-day FDA review.

K860537 · The Clell Corp. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1986
Decision
65d
Days
Class 1
Risk

K860537 is an FDA 510(k) clearance for the THE CELL CARE SYSTEM. Classified as Monitor, Bed Patient (product code KMI), Class I - General Controls.

Submitted by The Clell Corp. (Arlington, US). The FDA issued a Cleared decision on April 17, 1986 after a review of 65 days - a notably fast clearance cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.2400 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all The Clell Corp. devices

FDA 510(k) Submission Details - K860537

510(k) Number K860537 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 11, 1986
Decision Date April 17, 1986
Days to Decision 65 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
64d faster than avg
Panel avg: 129d · This submission: 65d
Pathway characteristics
Predicate-based equivalence.

KMI Device Classification - Class 1, General Controls

Product Code KMI Monitor, Bed Patient
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 880.2400
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.